Officer Files Intent to Sell Over $370K in Viemed Healthcare Shares
VMD sits 55% above its 52-week low of $5.93.
Summary
An officer of Viemed Healthcare, Inc. has filed a Form 144 indicating an intent to sell 40,232 common shares, valued at approximately $370,420, following a recent prior sale.
Key Events · Ownership and Investor Activity · VMD
-
Officer Intends to Sell Shares
Michael Brandon Moore, an officer of Viemed Healthcare, Inc. (via MOORE FASTER LLC), has filed a Form 144 to sell 40,232 common shares.
-
Significant Value of Proposed Sale
The proposed sale has an approximate market value of $370,420.05.
-
Follows Recent Insider Sale
This intent to sell follows a previous sale of 31,570 shares by the same entity on March 18, 2026, for gross proceeds of $297,345.20.
-
Conflicting Signal with Repurchase Program
This insider selling intent comes shortly after the company announced a new share repurchase program on March 16, 2026, creating a mixed signal regarding insider sentiment.
Analysis · VMD · Industrial Applications And Services
An officer of Viemed Healthcare, Inc. has filed a Form 144 indicating an intent to sell a notable amount of shares. This proposed sale, valued at over $370,000, follows a previous sale by the same entity just yesterday. This insider selling activity presents a conflicting signal, especially as the company recently authorized a new share repurchase program. Investors should monitor for the actual execution of this planned sale.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VMD was trading at $9.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $355.9M. The 52-week trading range was $5.93 to $10.06. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.